---
title: ADAMTS13 RECOVERY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER CAPLACIZUMAB
  THERAPY. THE SPANISH REGISTRY
date: '2024-01-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38237147/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240119170724&v=2.18.0
source: Blood
description: Caplacizumab prevents the interaction between von Willebrand factor and
  platelets, and is used to treat immune thrombotic thrombocytopenic purpura (iTTP).
  Its administration has been associated with a delay in ADAMTS13 activity restoration
  after plasma exchange (PEX) suspension. We analyzed the outcomes of 113 iTTP episodes,
  75 of which were treated with caplacizumab, in 108 patients from the Spanish Registry
  of Thrombotic Thrombocytopenic Purpura. Caplacizumab shortened the time to ...
disable_comments: true
---
Caplacizumab prevents the interaction between von Willebrand factor and platelets, and is used to treat immune thrombotic thrombocytopenic purpura (iTTP). Its administration has been associated with a delay in ADAMTS13 activity restoration after plasma exchange (PEX) suspension. We analyzed the outcomes of 113 iTTP episodes, 75 of which were treated with caplacizumab, in 108 patients from the Spanish Registry of Thrombotic Thrombocytopenic Purpura. Caplacizumab shortened the time to ...